Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Pola Pharma
Shinagawa/Tokyo-to/Saitama Prefecture, Japanpola-pharma.co.jp ↗
- Ownership
- Private
- Employees
- ~252
- Development stage
- Other
01
Overview
Pola Pharma specializes in dermatology with a portfolio of branded and generic products. It has commercialized drugs such as carglumic acid for metabolic disorders and has manufacturing capabilities for topical and injectable formulations. The company was acquired by Sun Pharmaceutical Industries to strengthen Sun’s dermatology presence in Japan. As of the acquisition, annual revenues were approximately $108 million with a net loss of $7 million for FY2017.
- Therapeutic areas
- DermatologyMetabolic DisordersOncology
- Modalities
- Small moleculeInjectables
- Industry
- Biotech
Beyond the preview
Go deeper on Pola Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pola Pharma.